Evidence map›Paper›PMID 33237475›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2021

The temporal course of COVID-19 anosmia and relation to other clinical symptoms.

Aytug Altundag, Ozlem Saatci, Deniz Esin Tekcan Sanli, Ozge Arici Duz, Ahmet Necati Sanli, Oktay Olmuscelik, Dastan Temirbekov, Sedat Giray Kandemirli, Aysegul Batioglu Karaaltin

Open access · bronzeAbstract read
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Systematic review and meta-analysis of olfactory and gustatory dysfunction in COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Pooled it
  2. Trial
  3. Review
  4. Prevalence and Factors Associated with Olfactory Dysfunction in Individuals with COVID-19 in Brazil: A Study of 20,669 Cases from 2020 to 2021.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2024
    Article
  5. Recovery Patterns of COVID-19 Related Smell Disorders: An Analysis of the Available Evidence.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2023
    Article
  6. Article
  7. Article
  8. Comparison of the Healing Effect of Nasal Saline Irrigation with Triamcinolone Acetonide Versus Nasal Saline Irrigation alone in COVID-19 Related Olfactory Dysfunction: A Randomized Controlled Study.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Results from psychophysical tests of smell and taste during the course of SARS-CoV-2 infection: a review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Anosmia as a predictor for post-COVID-19 fatigue syndrome.The Lancet regional health. Europe · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Aytug AltundagDepartment of Otorhinolaryngology, Biruni University, Istanbul, Turkey.
Ozlem SaatciDepartment of Otorhinolaryngology, Istanbul Sancaktepe, Education and Research Hospital, Istanbul, Turkey.
Deniz Esin Tekcan SanliDepartment of Radiology, Acıbadem Kozyatagi Hospital, Istanbul, Turkey.
Ozge Arici DuzDepartment of Neurology, Istanbul Medipol University, Istanbul, Turkey.
Ahmet Necati SanliDepartment of General Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey. ahmetnecatisanli@gmail.com.ORCID http://orcid.org/0000-0002-1483-8176
Oktay OlmuscelikDepartment of Internal Medicine, Istanbul Medipol University, Istanbul, Turkey.
Dastan TemirbekovDepartment of Otorhinolaryngology, Medicalpark Florya Hospital, Istanbul, Turkey.
Sedat Giray KandemirliDepartment of Radiology, The University of Iowa, Iowa, USA.
Aysegul Batioglu KaraaltinDepartment of Otorhinolaryngology, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Istanbul Medipol University · TRIstanbul University-Cerrahpaşa · TRBiruni University · TRIstanbul Eye Hospital · TRUniversity of Iowa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to define the clinical course of anosmia in relation to other clinical symptoms.

methods135 patients with COVID-19 were reached by phone and subsequently included in the study. Olfactory functions were evaluated using a questionnaire for assessment of self-reported olfactory function. Patients were divided into four subgroups according to the presence of olfactory symptoms and temporal relationship with the other symptoms: group1 had only olfactory complaints (isolated, sudden-onset loss of smell); group2 had sudden-onset loss of smell, followed by COVID-19 related complaints; group3 initially had COVID-19 related complaints, then gradually developed olfactory complaints; and group4 had no olfactory complaints.

resultsIn total, 59.3% of the patients interviewed had olfactory complaints during the disease course. The olfactory dysfunction severity during COVID-19 infection was significantly higher in group1 compared to groups 2 and 3. In groups1-3, the odor scores after recovery from COVID-19 disease were significantly lower compared to the status prior to disease onset. The residual olfactory dysfunction was similar between groups1 and 2, but was more evident than group3. Mean duration for loss of smell was 7.8 ± 3.1 (2-15) days. Duration of loss of smell was longer in groups1 and 2 than in group3. Odor scores completely returned back to the pre-disease values in 41 (51.2%) patients with olfactory dysfunction. Rate of complete olfactory dysfunction recovery was higher in group3 compared to groups1 and 2.

conclusionIn isolated anosmia cases, anosmia is more severe, and complete recovery rates are lower compared to the patients who have other clinical symptoms. LEVEL OF EVIDENCE: Level 4.

Indexed as

COVID-19Olfaction DisordersAnosmiaHumansSARS-CoV-2SmellAnosmiaCOVID-19Olfactory dysfunctionRecoverableSudden

Identifiers

PMID33237475
PMCPMC7686554
OpenAlexW3108559441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.